Bessemer Venture Partners

Bessemer Venture Partners is one of the oldest venture firms in the United States, with a lineage that traces back to the original Carnegie steel fortune and a modern practice that has made it one of the most consistent producers of public-company outcomes in the last two decades, particularly in cloud software, vertical SaaS, and healthcare technology. Bessemer is also unusual among elite firms in publishing its thesis work openly: the firm’s roadmaps on cloud, healthcare, vertical SaaS, and AI infrastructure are the most-cited pieces of investor content in the industry, and they are not marketing fluff, they are the actual frameworks the partnership uses to source. For healthcare and AI founders, the most relevant nodes are the healthcare practice led by partners including Steve Kraus, Sofia Guerra, Morgan Cheatham, and Andrew Hedin, which has produced exits and category-defining companies including Bright Health, Hims, AbleTo, AppDynamics-adjacent infra, and a long tail of specialty digital health platforms. Bessemer’s healthcare thesis is consistent across cycles: care delivery models with payer-aligned economics, infrastructure layers that sit between providers and payers, vertical SaaS for sub-specialty workflows, and now AI-native applications in clinical documentation, revenue cycle, and medical imaging. The firm writes from seed through growth, with seed checks typically starting around one to three million, Series A leads in the eight to fifteen million range, Series B and beyond scaling into the tens to low hundreds, and a growth practice that can lead pre-IPO rounds. Geography is global by intent but US- and Israel-heavy in practice, with offices in San Francisco, New York, Boston, London, Bangalore, and Tel Aviv; the firm has been more active in India than most of its peers and has a credible Latin America practice as well. Founders who should approach Bessemer are healthcare technology, AI infrastructure, and vertical SaaS founders who have either a strong technical wedge or a clear payer- or provider-economics story, and who appreciate a partnership that publishes its thinking and expects you to engage with it. Bessemer is particularly receptive to second- and third-time founders, to clinicians turned operators, and to engineers from Big Tech who have a non-obvious healthcare insight. The firm is less obvious for therapeutics, devices requiring long FDA cycles, and pure consumer health plays without a software or platform angle, although it does occasionally cross over into hardware-software hybrids where the data layer is the asset. The best entry path is a partner-specific outreach: read the relevant roadmap, identify the partner whose name is on it, find a portfolio CEO or shared LP, and send a tight one-page memo with the wedge, the metrics, and the explicit reason this partner should care. Cold inbound through the website does work at Bessemer better than at most peer firms, especially for seed, but a warm intro still wins on response time. When you pitch, lead with the one piece of customer evidence that is hardest to fake (a signed enterprise contract with a health system, a real cohort retention curve, a model output that beats a published benchmark in your specialty) and let the partner pull on the thread. Bessemer’s diligence is rigorous but founder-respectful, and they tend to give a fast no, which is itself a feature. Caveats: the firm is large enough to have multiple partners interested in adjacent themes, so make sure you are pitching the right person before you go deep; valuations at Bessemer are market but not above-market, so founders who want a frothy mark from a brand-name firm sometimes get a cleaner offer from a more aggressive solo capitalist; and post-investment, the partner’s involvement scales with their conviction, so the pitch is not just for the check, it is for the partner’s calendar.